Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MW02 versus Lucentis in neovascular age-related macular degeneration
ChiCTR2100042994Phase 3Recruiting
- Sponsor
- Mabwell
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of MW02 in exudative macular degeneration (3 arms), sponsored by Mabwell. Primary endpoint: Best-corrected visual acuity. Started Mar 2021; status: recruiting.
02
Drugs
MW02
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on ChiCTR2100042994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100042994.